Table 2.

Demographic and Clinicopathologic Factors in Melanoma Patients Undergoing Inguino-femoral Lymph Node Dissection (ILND)

	Fibrin sealant group, n = 16		Control group, n = 14
Variable	No.a	% of total	No.a	% of total	P value
Median age, years (range)	52 (38–91)		60 (18–73)		0.79
Sex, male/female	12/4	75/25	7/7	50/50	0.16
Median BMI, kg/m2 (range)	28.3 (19.6–42.1)		32.3 (21–48.6)		0.15
Comorbidities
Tobacco use	1	6	2	14	0.58
Diabetes	1	6	4	29	0.16
AJCC tumor stage					1.00
III	14	88	13	93
IV	2	12	1	7
Melanoma treatment prior to ILND
Surgery					0.34
None/FNA	5	31	4	29
SLN biopsy	6	38	8	57
Excisional biopsy/WLE	5	31	2	14
Systemic therapy					0.27
Chemotherapy	2	12	0		0.48
Interferon	1	6	2	14	0.59
Interleukin-2	1	6	0		1.00

BMI, body mass index; AJCC, American Joint Committee on Cancer; FNA, fine needle aspiration; SLN, sentinel lymph node; WLE, wide local excision.

^aData are number of patients unless otherwise indicated.